Sarah Castillo
Family Medicine · Lincoln, NENPI 1700141850
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 46.1% of the total. 2025 is the largest year on record at $555, more than ten times the $24 reported in 2019.
Across 64 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$499
- Otsuka America Pharmaceutical, Inc.$107
- Novo Nordisk$59
- Amgen$56
- Novartis$53
- Pfizer$44
- plus $266 from 15 others
What the payments were for
- Food & beverage$1,084100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $499 |
| Otsuka America Pharmaceutical, Inc. | 6 | $107 |
| Novo Nordisk | 4 | $59 |
| Amgen | 4 | $56 |
| Novartis | 3 | $53 |
| Pfizer | 3 | $44 |
| Lilly USA, LLC | 2 | $26 |
| Boston Scientific | 1 | $24 |
| Biogen | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Organon | 1 | $20 |
| Abbott | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$1,084 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $102,870 |
| RexultiBrexpiprazole | 51 | $92,310 |
| JardianceEmpagliflozin | 83 | $80,366 |
| MounjaroTirzepatide | 55 | $58,711 |
| EliquisApixaban | 58 | $37,620 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $28,151 |
| Nurtec OdtRimegepant Sulfate | 19 | $27,803 |
| VraylarCariprazine Hcl | 18 | $26,546 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $21,321 |
| OxycontinOxycodone Hcl | 17 | $21,310 |
| XareltoRivaroxaban | 23 | $20,905 |
| LinzessLinaclotide | 25 | $16,805 |
| GemtesaVibegron | 25 | $16,312 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $15,642 |
| EntrestoSacubitril/Valsartan | 11 | $11,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $59 | $113,350102 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $107 | $92,31051 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $15 | $91,27096 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $44 | $71,16496 claims |
| Lilly USA, LLCMounjaro | $26 | $58,71155 claims |
| AbbVieVraylar, Linzess | $499 | $43,35143 claims |
| Johnson & JohnsonXarelto | $21 | $20,90523 claims |
| NovartisEntresto | $53 | $11,23711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Lincoln
- Michael IsraelLincoln$375K
- Randy KohlLincoln$67K
- Matthew GlennLincoln$17K
- Uma NookaLincoln$12K
- Kylie ParshallLincoln$12K
- Michael HuffmanLincoln$11K
- Gary van ErtLincoln$10K
- Kelly PierceLincoln$10K
- Charles KreshelLincoln$10K
- Mark ButlerLincoln$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.